Spots Global Cancer Trial Database for Selecting a Favorable KIR Donor in Unrelated HCT for AML
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Selecting a Favorable KIR Donor in Unrelated HCT for AML
Official Title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Study ID: NCT01288222
Conditions
Interventions
Study Description
Brief Summary: Donors with favorable KIR B haplotype gene content have yielded reduced relapse risk and improved leukemia free survival (LFS) in retrospective analyses of unrelated donor (URD) hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML). Specifically, donors with more KIR B gene content and those who are homozygous for the centromeric (Cen) B haplotype genes (as opposed to the telomeric (Tel) genes confer the most protective effect. This study proposes to prospectively test and validate the utility and effectiveness of further informing URD identification and selection by KIR genotyping as a supplement to HLA matching and the other variables known or suspected to indicate the best URD for a patient. Hypotheses: 1. Favorable KIR donors will improve protection against relapse and improve leukemia free survival (LFS) after URD HCT for AML. 2. Directed study procedures for rapid KIR genotyping and reporting to searching Transplant Centers (TC) can inform donor search and selection without delay in donor availability for HCT.
Detailed Description: Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR donor.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
Emory University, Atlanta, Georgia, United States
University of Chicago Medical Center Cancer Center, Chicago, Illinois, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Kansas University Cancer Center, Kansas City, Kansas, United States
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
New York Presbyterian Weill Cornell Medical Center, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Baylor Sammons Cancer Center, Dallas, Texas, United States
M.D. Anderson Cancer Center, Houston, Texas, United States
Methodist Healthcare System of San Antonio, San Antonio, Texas, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Contact Details
Name: Daniel Weisdorf, M.D.
Affiliation: Masonic Cancer Center, University of Minnesota
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
